Corvus Pharmaceuticals
CRVS
88 hedge funds and large institutions have $115M invested in Corvus Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 26 increasing their positions, 23 reducing their positions, and 13 closing their positions.
145% more call options, than puts
Call options by funds: $4.72M | Put options by funds: $1.93M
23% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 13
13% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 23
4% more funds holding
Funds holding: 85 → 88 (+3)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
5.45% less ownership
Funds ownership: 58.7% → 53.26% (-5.4%)
43% less capital invested
Capital invested by funds: $202M → $115M (-$86.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$6.98M |
| 2 |
DA
DCF Advisers
Greenwich,
Connecticut
|
+$1.88M |
| 3 |
Two Sigma Investments
New York
|
+$1.31M |
| 4 |
Morgan Stanley
New York
|
+$1.3M |
| 5 |
Two Sigma Advisers
New York
|
+$1.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Samlyn Capital
New York
|
-$12.3M |
| 2 |
DM
Deerfield Management
New York
|
-$5.35M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.39M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.14M |
| 5 |
Goldman Sachs
New York
|
-$1.02M |
CRVS Hedge Fund Activity: Q1 2025 in Review
88 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Corvus Pharmaceuticals (CRVS) for Q1 2025, worth a combined $115M — down 43% from $202M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new CRVS positions and 13 closed out — a net gain of 3 holders — while 26 added to existing stakes and 23 trimmed.
The largest buyer was Millennium Management, adding an estimated $6.98M. The largest seller was Samlyn Capital, cutting an estimated $12.3M.
- 88 institutional investors held Corvus Pharmaceuticals (CRVS) as of Q1 2025, up from 85 in Q4 2024.
- Funds reported $115M of Corvus Pharmaceuticals stock for Q1 2025, down 43% quarter-over-quarter.
- 16 funds opened new Corvus Pharmaceuticals positions in Q1 2025 and 13 closed out, a net change of +3 holders.
- The largest Corvus Pharmaceuticals buyer in Q1 2025 was Millennium Management, an estimated $6.98M added.
- The largest Corvus Pharmaceuticals seller in Q1 2025 was Samlyn Capital, an estimated $12.3M sold.
Based on aggregated 13F filings for Q1 2025.